Your browser doesn't support javascript.
loading
Topical tacrolimus therapy for vitiligo: therapeutic responses and skin messenger RNA expression of proinflammatory cytokines.
Grimes, Pearl E; Morris, Robert; Avaniss-Aghajani, Erik; Soriano, Teresa; Meraz, Maria; Metzger, Allan.
Afiliação
  • Grimes PE; Vitiligo and Pigmentation Institute of Southern California, and the Division of Dermatology, David Geffen School of Medicine, University of California, Los Angeles, USA. pegrimesmd@earthlink.net
J Am Acad Dermatol ; 51(1): 52-61, 2004 Jul.
Article em En | MEDLINE | ID: mdl-15243524
ABSTRACT

BACKGROUND:

Previous studies have documented humoral and cell-mediated immunologic defects in patients with vitiligo.

OBJECTIVE:

This 24-week study assessed the efficacy and safety of tacrolimus 0.1% ointment in patients with generalized vitiligo as well as the pretreatment and post-treatment expression of cytokines in the depigmented and normal skin of patients compared with controls.

METHODS:

Twenty-three patients were enrolled in this investigation, and 19 patients completed the study; 8 were male and 11 were female. Fifteen age-, race-, and sex-matched control subjects were also included. Patients were treated with tacrolimus 0.1% ointment applied twice daily. Repeat evaluations were performed at 4, 8, 12, 16, 20, and 24 weeks. Three-millimeter punch biopsy specimens were taken from the depigmented, non-sun-exposed skin and adjacent normal skin of patients at baseline and 24 weeks, and from normal, non-sun-exposed skin of controls. Cellular messenger RNA expression for interleukin 2 (IL-2), IL-4, IL-10, tumor necrosis factor alfa (TFN-alpha), and interferon gamma (IFN-gamma) were determined by real-time quantitative polymerase chain reaction.

RESULTS:

At 24 weeks, 17 of 19 patients (89%) achieved varying levels of repigmentation. There was a statistically significant decrease in overall disease severity scores at 24 weeks. Thirteen patients (68%) had greater than 75% repigmentation of face and/or neck lesions. Signs and symptoms of irritation were minimal. At baseline, compared with healthy controls, vitiligo patients demonstrated a statistically significant increase in the expression of IFN-gamma in involved and adjacent uninvolved skin (P=.05 and P=.02, respectively); significantly increased TNF-alpha expression in involved and uninvolved skin (P=.01 and P=0.02, respectively); and significantly increased IL-10 expression in involved and uninvolved skin (P=.01 and P=.04, respectively). Posttreatment, TNF-alpha expression decreased in the depigmented and adjacent uninvolved skin (P <.001). There was no statistically significant change in IL-10 or IFN-gamma posttreatment. These data suggest that tacrolimus 0.1% ointment is a safe and effective therapy for patients with vitiligo. It further suggests that an imbalance in local cytokine expression may play a role in the pathogenesis of vitiligo. Suppression of TNF-alpha after topical tacrolimus application may be associated with repigmentation of vitiligo.
Assuntos
Buscar no Google
Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Vitiligo / Tacrolimo / Imunossupressores Limite: Adult / Female / Humans / Male / Middle aged Idioma: En Revista: J Am Acad Dermatol Ano de publicação: 2004 Tipo de documento: Article País de afiliação: Estados Unidos
Buscar no Google
Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Vitiligo / Tacrolimo / Imunossupressores Limite: Adult / Female / Humans / Male / Middle aged Idioma: En Revista: J Am Acad Dermatol Ano de publicação: 2004 Tipo de documento: Article País de afiliação: Estados Unidos